The global cell culture media market is poised for significant growth, with an expected market value of USD 3,513.8 million in 2024, projected to expand to USD 6,699.93 million by 2034. This growth reflects a compound annual growth rate (CAGR) of 6.66% during the forecast period, driven by increasing demand for biopharmaceutical production, advancements in research and development, and the growing adoption of cell culture technologies in various industries.
Cell culture media are essential for maintaining the viability and functionality of cells in laboratory conditions, and they play a critical role in the production of vaccines, monoclonal antibodies, and other biologics. The rising prevalence of chronic diseases, such as cancer, autoimmune disorders, and metabolic diseases, has significantly boosted the demand for therapeutic proteins and biologic drugs, driving the need for effective cell culture media.
Additionally, the growing focus on regenerative medicine and personalized therapies is further fueling the demand for high-quality culture media. The market is also benefitting from advancements in media formulations, such as serum-free and chemically defined media, which enhance the efficiency and scalability of cell culture processes.
Request a Sample Copy of This Report Now: https://www.fmisamplereport.com/sample/rep-gb-14366
Key Takeaways:
- The global cell culture media market is expected to grow from USD 3,513.8 million in 2024 to USD 6,699.93 million by 2034, at a CAGR of 6.66%.
- Rising demand for biopharmaceuticals, vaccines, and personalized therapies is driving the market’s expansion.
- Advancements in media formulations and a growing focus on regenerative medicine are further supporting market growth.
- The increasing prevalence of chronic diseases is expected to accelerate demand for cell culture technologies in drug development and production.
Key Market Drivers
The market generated an estimated revenue of USD 2,505.29 million in 2019. The market grew at a 7.00% CAGR and added a staggering revenue of USD 1,008.51 million. Several reasons can be attributed to this growth:
- The cell culture media industry has experienced significant growth due to the increasing demand for biopharmaceuticals.
- The widespread adoption of cell-based therapies has also fueled the market’s expansion as these treatments gain prominence in various medical applications.
- The market has benefited from the rising significance of cell culture media in drug discovery, where precise cell environments are crucial for effective research and development.
- Government support and increased research funding in the fields of biotechnology and life sciences have also played a crucial role in the market’s growth.
- The global expansion of biotechnology industries has contributed to the market’s upswing, with companies exploring new avenues and applications for cell culture media.
- Ongoing advancements in cell culture media formulations and technologies have driven market growth, offering improved and specialized solutions for cell-based research.
- The growing awareness about personalized medicine approaches has spurred the adoption of cell culture media, as tailored treatments based on individual characteristics gain traction.
Competitive Landscape
The global cell culture media market is characterized by the presence of key players like Avantor, Inc., Thermo Fisher Scientific, Inc., Caisson Laboratories Inc., Becton Dickinson and Company, Lonza Group AG, Bio-Rad Laboratories, Inc., General Electric Company, etc.
Many companies are investing heavily in research and development to create innovative and specialized cell culture media formulations. This includes developing serum-free and defined media, optimizing existing formulations, and incorporating advanced technologies to meet the evolving needs of biopharmaceutical and life sciences research.
Recent Developments
- On July 12, 2023, Merck announced the expansion of its Lenexa, Kansas facility, making it the company’s largest dry powder cell culture media facility and Center of Excellence in North America.
- In October 2023, London-based startup Multus Biotechnology focused on cutting the cost of cell culture media for cultivated meat by leveraging AI to optimize formulation efficiency. The startup addresses challenges in ingredient quality, scalability, and bioprocess productivity, aiming to enhance the sustainability and cost-effectiveness of cell culture media.
- On July 27, 2023, MilliporeSigma invested $25 million to expand its cell culture media production facility in Lenexa, Kansas. The expansion included 98,000 ft2 of lab space, reinforcing the company’s commitment to meeting the increasing demand for cell culture media. Lenexa now serves as one of the three global centers of excellence for dry powder cell culture media manufacturing.
Key Companies in the Market
- Avantor, Inc.
- Thermo Fisher Scientific, Inc.
- Caisson Laboratories Inc.
- Becton Dickinson and Company
- Lonza Group AG
- Bio-Rad Laboratories, Inc.
- General Electric Company
- Cell Culture Technologies LLC
- Corning Incorporated
- Fujifilm Holdings Corporation
- Hi Media Laboratories Pvt. Ltd.
- Merck & Co., Inc.
Market Segmentation
By Type:
- Serum-free Media
- CHO Media
- HEK 293 Media
- BHK Media
- VERO Cell Media
- Insect Cell Media
- Serum-free Stem Cell Media
- CAR T-cell Media
- Other Serum-free Media
- Classical Media & Salts
- Stem Cell Culture Media
- Specialty Media
- Chemically defined Media
- Other Cell Culture Media
By Application:
- Biopharmaceutical Production
- Monoclonal antibodies
- Cancer Research
- Vaccines production
- Other therapeutic proteins
- Diagnostics
- Drug Screening & Development
- Tissue Engineering & Regenerative Medicine
- Cell and gene therapy
- Other tissue engineering & regenerative medicine applications
- Other Application
By End User:
- Pharmaceutical & Biotechnology Companies
- Hospitals & Diagnostic Laboratories
- Research & Academic Institutes
- Others
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East and Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
